Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treatedwith liraglutide: Results from the LEADER randomized trial

Diabetes Care

Volumn 40, Issue 7, 2017, Pages 966-972

  Steinberg, William M ^a   Buse, John B ^b   Ghorbani, Marie Louise Muus ^c   Ørsted, David D ^c   Nauck, Michael A ^d  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NOVO NORDISK A S   (Denmark)

^d ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; LIRAGLUTIDE; PLACEBO; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT;

ACUTE PANCREATITIS; ADULT; AGED; AMYLASE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PREDICTION; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ACUTE DISEASE; BLOOD; CARDIOVASCULAR DISEASE; MIDDLE AGED; RISK FACTOR;

ACUTE DISEASE; AMYLASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPASE; LIRAGLUTIDE; MALE; MIDDLE AGED; PANCREATITIS; RISK FACTORS;

EID: 85021091596     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-2747     Document Type: Conference Paper

References (35)

1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
2. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539
3. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetesmellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12:766-771
4. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidylpeptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012;18:472-477
5. Malloy J, Gurney K, Shan K, Yan P, Chen S. Increasedvariability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjectswith type 2 diabetes. DiabetesMetab Syndr Obes 2012;5:419-424
6. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patientswith type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32:834-838
7. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794-797
8. Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014;57:1320-1324
9. Buse JB, Bethel MA, Green JB, et al.; TECOS Study Group. Pancreatic safety of sitagliptin in the TECOS Study. Diabetes Care 2017;40:164-170
10. Abbas AS, Dehbi HM, Ray KK. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials. Diabetes Obes Metab 2016;18:295-299
11. Tenner S, Dubner H, Steinberg W. Predicting gallstone pancreatitis with laboratory parameters: a meta-analysis. Am J Gastroenterol 1994; 89:1863-1866
12. Marso SP, Poulter NR, Nissen SE, et al. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. Am Heart J 2013;166:823-830.e5
13. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER SteeringCommittee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
14. Steinberg WM, Nauck MA, Zinman B, et al.; LEADER Trial investigators. LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014;43:1223-1231
15. Banks PA, Bollen TL, Dervenis C, et al.; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102-111
16. Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analysesof pooleddata fromthe SCALE clinical development program. Diabetes Care 2017;40:839-848
17. Steinberg WM, DeVries JH, Wadden TA, Jensen CB, Svendsen CB, Rosenstock J. Elevated serumlipase activity in adultswith type 2 diabetes and no gastrointestinal symptoms (Abstract). Gastroenterology 2012;142(Suppl. 1):A422
18. Junge W, Mályusz M, Ehrens HJ. The role of the kidney in the elimination of pancreatic lipase and amylase fromblood. J Clin ChemClin Biochem 1985;23:387-392
19. Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol 2015;28:391-402
20. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155:1280-1290
21. Sonne DP, Vilsbøll T, Knop FK. Pancreatic amylase and lipase plasma concentrations are unaffected by increments in endogenous GLP-1 levels following liquid meal tests. Diabetes Care 2015; 38:e71-e72
22. Koehler JA, Baggio LL, Cao X, et al. Glucagonlike peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 2015;64:1046-1056
23. Nyborg NC,Mølck AM,Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-1249
24. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-4488
25. Vilsbøll T, ChristensenM, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists onweight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
26. Wicker C, Puigserver A. Changes in mRNA levels of rat pancreatic lipase in the early days of consumption of a high-lipid diet. Eur J Biochem 1989;180:563-567
27. Wicker C, Puigserver A. Expression of rat pancreatic lipase gene ismodulated by a lipid-rich diet at a transcriptional level. Biochem Biophys Res Commun 1990;166:358-364
28. Tsai A, CowanMR, Johnson DG, Brannon PM. Regulation of pancreatic amylase and lipase gene expression by diet and insulin in diabetic rats. Am J Physiol 1994;267:G 575-G583
29. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
30. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257
31. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-661; quiz 644
32. Andersen V, Sonne J, AndersenM. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur J Clin Pharmacol 2001;57:517-521
33. Eland IA, van Puijenbroek EP, Sturkenboom MJ,Wilson JH, Stricker BH. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol 1999;94:2417-2422
34. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weightmanagement.NEngl JMed 2015;373:11-22
35. Meier JJ, Rosenstock J. Therapy: gastrointestinal safety of incretin therapies: arewe there yet? Nat Rev Gastroenterol Hepatol 2016;13:630-632